

1632



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE #5

Applicant(s): Rong XIANG, et al.)
Serial No. 10/090,238) Attorney Docket No.: (TSRI-830.0)
Filed: March 2, 2002) Group Art: 1632
For: DNA VACCINES ENCODING CEA)
AND A CD40 LIGAND AND METHODS OF)
USE THEREOF)
Examiner: Not Yet Assigned)

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D. C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, documents that may be material to the examination of this application are listed on the attached PTO-1449 form. Copies of each document are enclosed.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.


Serial No. 10/090,238
Filed: March 2, 2002

-2-

Also, there is reserved the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, and that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

By 
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180



Patent No.
Filed:


10/090,238
March 2, 2002

-3-

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence and attachments are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on 23 April 2003.


Talivaldis Cepuritis



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Applicant Number	10/090,238
		Filing Date	March, 2, 2002
		First Named Inventor	Rong XIANG, et al.
		Art Unit	1632
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	TSRI-830.0

RECEIVED

APR 30 2003

TECH CENTER 1600/2900

OTHER PRIOR ART–NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rong XIANG, et al., CLINICAL CANCER RESEARCH, Vol. 7, pp. 856s-864s (March 2001) (Suppl.).	
		James W. HODGE, et al., CANCER RESEARCH, Vol. 59, pp. 5800-5807 (November 15, 1999).	
		Erik KASS, et al., CANCER RESEARCH, Vol. 59, pp. 676-683 (February 1, 1999).	
		Stephen D. GILLIES, et al., JOURNAL OF IMMUNOLOGY, pp. 6195-6203 (1998).	
		Joanne P. McLAUGHLIN, et al., CANCER RESEARCH, Vol. 56, pp. 2361-2367 (May 15, 1996).	
		Shin SASAKI, et al., NATURE BIOTECHNOLOGY, Vol. 19, pp. 543-547 (June 2001).	
		Nicholas P. RESTIFO, NATURE BIOTECHNOLOGY, Vol. 19, pp. 527-528 (June 2001).	
		Wolfgang W. LEITNER, et al., CANCER RESEARCH, Vol. 60, pp. 51-55 (January 1, 2000).	
		N.P. RESTIFO, et al., GENE THERAPY, Vol. 7, pp. 89-92, (2000).	
		Andreas G. NIETHAMMER, et al., NATURE MEDICINE, Vol. 8 (12), pp. 1369-1375 (December, 2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.